Skip to content
Brit Fortune Place

Users Coming Off Anti-Obesity Medications Put On Pounds Far More Rapidly Compared to Those on Conventional Diets

Illustration of pharmaceutical syringe and scale
Obesity treatment often requires long-term strategies.

Fresh analysis indicates that patients who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who end conventional diet and exercise plans.

Research printed in a prominent medical journal shows that while overweight people often shed substantial amounts of their body weight while on the medication, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation.

"Individuals purchasing such medications should be informed of the potential of fast rebound weight gain when the therapy is stopped," warns researcher Dr. Susan Jebb.

That rate of regain implies a return to starting weight within about a year and a half.

Comparing Approaches

The analysis, which reviewed 37 of studies involving thousands of participants, contrasted the outcomes of the injectable medications with older methods.

Researchers emphasize that individuals who shed pounds through dieting generally have a slower creep back—perhaps 100 grams monthly—post-intervention.

Understanding the Quick Rebound

Experts believe the mechanism of the drugs accounts for the accelerated weight return.

GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which controls appetite.

"Artificially providing the hormone levels far above than normal might result in the body to generate a reduced amount of its own natural hormone, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition specialist.

"Withdrawal of this GLP-1 'fix' leads to hunger is unsuppressed, making binge eating a significant risk."

A Chronic Disease?

Health authorities suggest the jabs for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications.

Many experts say that, due to the likelihood of weight regain, the therapy should be considered ongoing.

This opinion is echoed by drug manufacturers, who state that the findings "underscore the chronic nature of excess weight," akin to managing diseases like diabetes.

User Experiences

People who have come off the medication report a powerful resurgence of appetite.

"It was like a switch flipping and you become ravenous," said an individual.

This challenge is exacerbated if individuals have not established sustainable lifestyle or habit changes during treatment.

Widespread Interest

Recent estimates indicate that a significant number of people in the UK have tried these injections in the past year, with interest continuing to grow.

  • Use is higher among females than men.
  • The 40s and 50s age group shows the greatest usage rates.
  • Many access the medications through private healthcare rather than public health services.

Ultimately, researchers stress that while GLP-1 drugs are effective agents for weight loss, they are not a standalone cure and long-term success likely depends on integrated lifestyle support.

JT
Written by

Jasmin Tran

Eleanor Whitmore is a seasoned financial analyst specializing in UK markets and personal wealth growth strategies.

Brit Fortune Place

Type to search articles.